For HPV-negative tumours, mutations are clustered within the ‘RTK-RAS-PI3K’ pathways and cell cycle regulation (CCND1), with common loss/inactivation of CDKN2A and TP53 tumour-suppressors and dysregulation of cell-proliferation and growth [11,43]. Here, CDKN2A is linked to neoplasm.